| Trial ID: | L6356 |
| Source ID: | NCT01106287
|
| Associated Drug: |
Mk-0941
|
| Title: |
Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01106287/results
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: MK-0941|DRUG: Comparator: Placebo
|
| Outcome Measures: |
Primary: Number of Participants Who Experienced One or More Adverse Events During the Study, Up to 30 days after the last dose of study drug|Number of Participants Who Discontinued Study Drug Due to an Adverse Event, Only treatment-emergent adverse events were examined for this outcome measure., Up to 6 weeks after the first dose of study drug |
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
13
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-10
|
| Completion Date: |
2010-03
|
| Results First Posted: |
2012-12-13
|
| Last Update Posted: |
2016-02-04
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01106287
|
